Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 63Breast Neoplasms 28Neoplasms 5Neoplasm Metastasis 3Leiomyoma 3Cardiovascular Diseases 3Polycystic Ovary Syndrome 2Neoplasms by Site 2Endometrial Neoplasms 2Breast Diseases 2Advanced Breast Cancer 2Stage II Prostate Adenocarcinoma 1Sleep Wake Disorders 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Sarcopenia 1Salivary Gland Neoplasms 1Salivary Gland Adenoma, Pleomorphic 1Prostatic Neoplasms, Castration-Resistant 1Prostatectomy 1Prostate Cancer With ≤10 Bone Metastases 1Prostate Cancer Metastatic Disease 1Prostate Cancer Metastatic 1Pelvic Pain 1Ovarian Neoplasms 1Osteoporosis 1Oligometastatic Prostate Carcinoma 1Obesity 1Non-alcoholic Fatty Liver Disease 1Metastatic Neuroendocrine Prostate Cancer 1

Interventions

ribociclib 1palbociclib 1giredestrant 1abemaciclib 1Gonadotropin-Releasing Hormone 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer × Gonadotropin-Releasing Hormone × Clear all
NCT06065748 2026-06-04

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Hoffmann-La Roche

Phase 3 Recruiting
1,050 enrolled
Breast

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡